DK2475372T4 - Fremgangsmåde til fremstilling af micro-RNA og dets terapeutiske anvendelse - Google Patents

Fremgangsmåde til fremstilling af micro-RNA og dets terapeutiske anvendelse Download PDF

Info

Publication number
DK2475372T4
DK2475372T4 DK10757747.0T DK10757747T DK2475372T4 DK 2475372 T4 DK2475372 T4 DK 2475372T4 DK 10757747 T DK10757747 T DK 10757747T DK 2475372 T4 DK2475372 T4 DK 2475372T4
Authority
DK
Denmark
Prior art keywords
rna
micro
preparation
therapeutic use
therapeutic
Prior art date
Application number
DK10757747.0T
Other languages
Danish (da)
English (en)
Other versions
DK2475372T3 (en
Inventor
Flemming Velin
Svend Lindenberg
Original Assignee
Velin Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42147287&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2475372(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Velin Pharma As filed Critical Velin Pharma As
Publication of DK2475372T3 publication Critical patent/DK2475372T3/en
Application granted granted Critical
Publication of DK2475372T4 publication Critical patent/DK2475372T4/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5094—Microcapsules containing magnetic carrier material, e.g. ferrite for drug targeting
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/10—Production naturally occurring

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
DK10757747.0T 2009-09-10 2010-09-10 Fremgangsmåde til fremstilling af micro-RNA og dets terapeutiske anvendelse DK2475372T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09169937 2009-09-10
PCT/EP2010/063313 WO2011029903A1 (en) 2009-09-10 2010-09-10 Method for the preparation of micro-rna and its therapeutic application

Publications (2)

Publication Number Publication Date
DK2475372T3 DK2475372T3 (en) 2017-10-23
DK2475372T4 true DK2475372T4 (da) 2020-11-30

Family

ID=42147287

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10757747.0T DK2475372T4 (da) 2009-09-10 2010-09-10 Fremgangsmåde til fremstilling af micro-RNA og dets terapeutiske anvendelse

Country Status (8)

Country Link
US (1) US9078914B2 (enExample)
EP (1) EP2475372B2 (enExample)
JP (1) JP5902088B2 (enExample)
CN (1) CN102573856B (enExample)
AU (1) AU2010294197C9 (enExample)
CA (1) CA2773619C (enExample)
DK (1) DK2475372T4 (enExample)
WO (1) WO2011029903A1 (enExample)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20030376A1 (it) 2003-07-31 2005-02-01 Univ Roma Procedimento per l'isolamento e l'espansione di cellule staminali cardiache da biopsia.
US11660317B2 (en) 2004-11-08 2023-05-30 The Johns Hopkins University Compositions comprising cardiosphere-derived cells for use in cell therapy
EP2475372B2 (en) 2009-09-10 2020-10-21 Velin-Pharma A/S Method for the preparation of micro-rna and its therapeutic application
EP2354246A1 (en) 2010-02-05 2011-08-10 febit holding GmbH miRNA in the diagnosis of ovarian cancer
US9845457B2 (en) 2010-04-30 2017-12-19 Cedars-Sinai Medical Center Maintenance of genomic stability in cultured stem cells
US9249392B2 (en) 2010-04-30 2016-02-02 Cedars-Sinai Medical Center Methods and compositions for maintaining genomic stability in cultured stem cells
US8716258B2 (en) 2010-06-04 2014-05-06 The Board Of Regents, The University Of Texas System Regulation of metabolism by miR-378
US10385314B2 (en) * 2010-08-16 2019-08-20 Exostem Biotec Ltd. Methods of generating oligodendrocytes and cell populations comprising same
US8642751B2 (en) 2010-12-15 2014-02-04 Miragen Therapeutics MicroRNA inhibitors comprising locked nucleotides
US9771617B2 (en) 2011-06-27 2017-09-26 Eisai R&D Management Co., Ltd. Microrna biomarkers indicative of alzheimer's disease
CN102296112B (zh) * 2011-08-09 2013-06-05 南京医科大学 人类非梗阻性无精子症相关的精浆微小核糖核酸标志物及其应用
US20140274789A1 (en) * 2011-08-11 2014-09-18 Andreas Keller Complex sets of mirnas as non-invasive biomarkers for psoriasis
US20140302068A1 (en) * 2011-09-09 2014-10-09 The Regents Of The University Of Colorado MicroRNA Biomarkers for Diagnosing Parkinson's Disease
US9428749B2 (en) 2011-10-06 2016-08-30 The Board Of Regents, The University Of Texas System Control of whole body energy homeostasis by microRNA regulation
CN104080911A (zh) * 2011-11-30 2014-10-01 不来梅大学 miRNA在胎盘组织中的表达
ITRM20110685A1 (it) 2011-12-23 2013-06-24 Internat Ct For Genetic En Gineering And Microrna per la rigenerazione cardiaca attraverso l induzione della proliferazione dei miociti cardiaci
US11286463B2 (en) 2012-03-08 2022-03-29 Advanced ReGen Medical Technologies, LLC Reprogramming of aged adult stem cells
WO2013170146A1 (en) 2012-05-10 2013-11-14 Uab Research Foundation Methods and compositions for modulating mir-204 activity
EP2861238A4 (en) 2012-06-05 2016-03-16 Capricor Inc OPTIMIZED METHODS FOR GENERATING CARDIAC STEM CELLS FROM CARDIAC TISSUE AND THEIR USE IN CARDIAC THERAPY
JP6208228B2 (ja) 2012-06-21 2017-10-04 ミラゲン セラピューティクス， インコーポレイテッド ロックド核酸モチーフを含むオリゴヌクレオチドベースの阻害剤
CN102727909B (zh) * 2012-06-28 2014-06-04 中国人民解放军总医院 一种抑制原发性肝癌生长和转移的新方法
CN102787117A (zh) * 2012-07-20 2012-11-21 苏州大学 微小rna用于调控b7-h2基因表达
US9828603B2 (en) 2012-08-13 2017-11-28 Cedars Sinai Medical Center Exosomes and micro-ribonucleic acids for tissue regeneration
CN103667282A (zh) * 2012-08-30 2014-03-26 苏州博泰安生物科技有限公司 前列腺癌分子标志物miR-628-3P及其应用
EP2916853B1 (en) * 2012-11-09 2020-05-06 Velin-Pharma A/S Compositions for pulmonary delivery
WO2014086243A1 (zh) * 2012-12-07 2014-06-12 中国科学院上海生命科学研究院 负向调控I型干扰素通路的miRNA分子及其应用
CN103173448A (zh) * 2013-02-07 2013-06-26 上海市胸科医院 早期肺腺癌miRNA特异表达谱及其反转录引物和用途
US9675633B2 (en) 2013-03-14 2017-06-13 Board Of Regents, The University Of Texas System miRNA for treating cancer and for use with adoptive immunotherapies
US20160017326A1 (en) * 2013-03-14 2016-01-21 The Trustees Of Princeton University Micrornas as functional mediators and biomarkers of bone metastasis
CN103157117B (zh) * 2013-03-19 2014-07-02 广州中国科学院先进技术研究所 一种调控肿瘤对trail耐受性的药物
JP6137894B2 (ja) * 2013-03-22 2017-05-31 国立大学法人京都大学 リポソーム−エキソソームハイブリッドベシクル及びその調製法
CN103194542B (zh) * 2013-04-28 2014-03-26 夏彦恺 人类胎儿生长受限相关的血清微小核糖核酸标志物及其应用
CN103205430B (zh) * 2013-04-28 2015-04-15 夏彦恺 人类重度子痫前期发生相关的血清微小核糖核酸标志物及其应用
WO2014189850A1 (en) 2013-05-20 2014-11-27 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Detection and treatment of irritable bowel syndrome
US9879260B2 (en) 2013-08-20 2018-01-30 The Board Of Regents Of The University Of Texas System Micro-RNA regulation of bone loss
WO2015042435A1 (en) * 2013-09-20 2015-03-26 Academia Sinica Treating diseases associated with pgc1-alpha by modulating micrornas mir-130a and mir-130b
US20160289763A1 (en) * 2013-11-13 2016-10-06 The Texas A&M University System Micro-rnas that modulate lymphangiogenesis and inflammatory pathways in lymphatic vessel cells
WO2015081263A1 (en) 2013-11-26 2015-06-04 Central Biomedia, Inc. Method and diet for immune enhanced donor blood
CN103623431B (zh) * 2013-12-05 2015-04-22 南京大学 miR181s在制备治疗急性肠炎药物中的应用
RU2548816C1 (ru) * 2013-12-16 2015-04-20 Мамонтова Марина Васильевна Способ выделения микрорнк из биологических жидкостей
WO2015091892A1 (en) * 2013-12-19 2015-06-25 Comprehensive Biomarker Center Gmbh Mirnas as non-invasive biomarkers for parkinson's disease
US10772911B2 (en) 2013-12-20 2020-09-15 Advanced ReGen Medical Technologies, LLC Cell free compositions for cellular restoration and methods of making and using same
WO2015095794A1 (en) 2013-12-20 2015-06-25 Advanced ReGen Medical Technologies, LLC Compositions for cellular restoration and methods of making and using same
ES2760263T3 (es) * 2014-03-21 2020-05-13 Genzyme Corp Tratamiento génico de la retinitis pigmentaria
KR101667650B1 (ko) * 2014-03-31 2016-10-20 숙명여자대학교산학협력단 ｍｉＲ-192, ｍｉＲ-215 또는 ｍｉＲ-194를 포함하는 인간 상염색체 우성 다낭신 치료용 약학 조성물
CN103937826B (zh) * 2014-04-04 2016-04-06 东华大学 一种中枢神经系统中特异表达miR-505的载体的制备方法
WO2015189345A2 (en) * 2014-06-13 2015-12-17 Universität Für Bodenkultur Wien Compositions and methods for the diagnosis and treatment of bone fractures and disorders
JP6566612B2 (ja) * 2014-06-27 2019-08-28 国立大学法人北海道大学 免疫体質又は免疫応答型を判定するためのバイオマーカー及び免疫応答型制御剤
JP6385732B2 (ja) * 2014-06-27 2018-09-05 国立大学法人北海道大学 免疫応答制御剤
CN105368822A (zh) * 2014-08-29 2016-03-02 香港大学 一种miRNA标记物、其方法和应用
CN105457039A (zh) * 2014-09-10 2016-04-06 洪挺祯 促进伤口愈合的制剂及其制备方法及使用方法
CN104306988B (zh) * 2014-09-25 2017-02-15 中国医学科学院基础医学研究所 miR‑431在制备治疗肌肉疾病的药物中的用途
US11357799B2 (en) 2014-10-03 2022-06-14 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy
CN104491878A (zh) * 2014-12-19 2015-04-08 青岛大学 一种含有miRNA-324的药物组合物及其用途
EP3247716A4 (en) 2015-01-20 2018-10-17 Miragen Therapeutics, Inc. Mir-92 inhibitors and uses thereof
CN104830858A (zh) * 2015-03-05 2015-08-12 中国人民解放军第四军医大学 一种与浆液性卵巢癌发生发展机制相关的microRNA分子及其应用
CN105647919A (zh) * 2015-04-01 2016-06-08 四川大学华西医院 一种microRNA-129-5p的检测试剂盒和检测方法
CN104940954B (zh) * 2015-06-23 2017-12-26 同济大学 MicroRNA‑7在制备抗胶质化药物中的应用
US10441601B2 (en) * 2015-06-30 2019-10-15 St. Jude Children's Research Hospital, Inc. Method for treating schizophrenia
WO2017004526A1 (en) * 2015-07-02 2017-01-05 University Of Louisville Research Foundation, Inc. EDIBLE PLANT-DERIVED MICROVESICLE COMPOSITIONS FOR DELIVERY OF miRNA AND METHODS FOR TREATMENT OF CANCER
CN105497915A (zh) * 2015-07-21 2016-04-20 青岛大学附属医院 miR-223-3p或miR-885-5p模拟物在制备治疗急性痛风性关节炎药物中的应用
CN105363042B (zh) * 2015-10-21 2022-05-06 圣诺生物医药技术(苏州)有限公司 一种药物组合物及其应用
CN105288658B (zh) * 2015-10-30 2018-08-28 中国人民解放军第三军医大学 miR-18a-5p抑制剂在制备防治骨质疏松药物中的应用
WO2017078099A1 (ja) 2015-11-06 2017-05-11 東レ株式会社 癌の治療及び／又は予防用医薬組成物
WO2017099238A1 (ja) 2015-12-10 2017-06-15 東レ株式会社 癌の治療及び／又は予防用医薬組成物
EP3402543B1 (en) 2016-01-11 2021-09-08 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction
JP6907939B2 (ja) 2016-01-28 2021-07-21 東レ株式会社 癌の治療及び／又は予防用医薬組成物
CN105854017A (zh) * 2016-03-01 2016-08-17 扬州大学 一种治疗β-地中海贫血的试剂及其应用
WO2017190000A1 (en) * 2016-04-29 2017-11-02 Advanced ReGen Medical Technologies, LLC Microrna compositions and methods of making and using same
US11351200B2 (en) 2016-06-03 2022-06-07 Cedars-Sinai Medical Center CDC-derived exosomes for treatment of ventricular tachyarrythmias
EP3498284B1 (en) 2016-08-09 2021-07-14 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
IT201600093825A1 (it) 2016-09-19 2018-03-19 Fondazione St Italiano Tecnologia Composizione farmaceutica di miRNA e suoi usi terapeutici.
EP3515459A4 (en) 2016-09-20 2020-08-05 Cedars-Sinai Medical Center CELLS DERIVED FROM CARDIOSPHERES AND THEIR EXTRACELLULAR VESICLES TO DELAY OR REVERSE AGING AND AGE-RELATED DISORDERS
WO2018139759A1 (ko) * 2017-01-26 2018-08-02 주식회사 바이오오케스트라 마이크로 rna를 이용한 알츠하이머병 진단방법
US11759482B2 (en) 2017-04-19 2023-09-19 Cedars-Sinai Medical Center Methods and compositions for treating skeletal muscular dystrophy
WO2018208969A1 (en) * 2017-05-09 2018-11-15 New York University Micrornas for treatment of neuropathic pain
CN108853131A (zh) * 2017-05-11 2018-11-23 北京捷腾生物科技有限公司 携带miR-185的外泌体及其用途
CN107412250B (zh) * 2017-05-11 2019-03-05 南京北恒生物科技有限公司 miR-193a-3p的应用
CN107287319B (zh) * 2017-07-13 2021-07-02 青岛大学 miRNA-485-5p核苷酸类似物及其反义核苷酸的应用和应用其的产品
KR101956315B1 (ko) * 2017-07-19 2019-03-08 국민대학교 산학협력단 파킨슨병 바이오마커로서의 miR494 및 이를 이용한 진단키트
CN107419022B (zh) * 2017-08-17 2021-03-16 武汉大学 与绝经后骨质疏松相关的miRNA标志物和试剂盒
CN107693535A (zh) * 2017-09-05 2018-02-16 上海市光华中西医结合医院 一种microRNA的应用
CN109722473A (zh) * 2017-10-31 2019-05-07 中国科学院深圳先进技术研究院 与骨代谢疾病相关的miRNA标志物miR-19b的应用
WO2019103300A1 (ko) * 2017-11-27 2019-05-31 (주)프로스테믹스 Mirna를 포함하는 상처 치료 또는 피부 개선용 조성물
US11660355B2 (en) 2017-12-20 2023-05-30 Cedars-Sinai Medical Center Engineered extracellular vesicles for enhanced tissue delivery
EP3740576A4 (en) 2018-01-18 2021-10-20 Advanced Regen Medical Technologies, LLC THERAPEUTIC COMPOSITIONS AND THEIR PREPARATION AND USE METHODS
EP3749344A4 (en) 2018-02-05 2022-01-26 Cedars-Sinai Medical Center METHODS OF THERAPEUTIC USE OF EXOSOMES AND Y-RNAS
CN108853132A (zh) * 2018-05-22 2018-11-23 深圳先进技术研究院 一种miR-340调控IL-17A表达的用途
EP3820483A4 (en) * 2018-07-13 2023-03-01 Yale University COMPOSITIONS AND METHODS FOR THE TREATMENT OF ENDOMETRIOSIS
WO2020030750A1 (en) 2018-08-08 2020-02-13 Theramir Ltd Microrna-based therapy targeted against lcp-1 positive cancers
CN110038026B (zh) * 2019-03-27 2021-08-17 浙江大学 mmu-miR-218-5p在制备抑制胚胎着床的药物中的应用
CN110075122B (zh) * 2019-05-09 2021-04-20 复旦大学附属中山医院 一种肝癌治疗性外泌体药物
US11198908B2 (en) 2019-06-17 2021-12-14 Biorchestra Co., Ltd. Method for diagnosis of Alzheimer's disease using microRNA
MX2022000074A (es) * 2019-07-02 2022-04-06 Ohio State Innovation Foundation Terapias para enfermedades neurodegenerativas que usan el eje piel cerebro.
KR102323535B1 (ko) * 2019-07-10 2021-11-08 주식회사 엠디헬스케어 당뇨병성 신증 진단용 조성물
IT201900017234A1 (it) * 2019-09-25 2021-03-25 Int Centre For Genetic Engineering And Biotechnology Anti-miRNA per il trattamento del leiomioma
CN110791560B (zh) * 2019-11-06 2021-09-14 中国医学科学院医药生物技术研究所 一种用于阿尔茨海默病诊断和/或治疗的miRNA标志物
TW202134437A (zh) * 2019-11-29 2021-09-16 比利時商諾瓦迪生物科學公司 用於預防及治療組織疾病之基於ｍｉＲＮＡ之醫藥組成物及其用途
CN111330008B (zh) * 2020-02-11 2021-02-05 四川大学 miR-93抑制剂在制备修复牙本质的药物中的用途
CN111529713B (zh) * 2020-05-11 2021-10-22 山东大学 一种AuNPs/miR-140复合物及其制备方法和应用
CN111840310B (zh) * 2020-07-27 2021-11-26 中国农业科学院兰州兽医研究所 ssc-miR-151-3p在制备调节猪繁殖与呼吸综合征病毒复制的药物中的应用
KR102371833B1 (ko) * 2020-09-14 2022-03-08 서울대학교산학협력단 GDF11 유전자의 발현을 조절하는 microRNA 및 이를 함유하는 조성물
CN112410414B (zh) * 2020-10-09 2022-07-08 嘉兴市妇幼保健院 孕妇血清外泌体miRNA标志物在制备胎儿先心病早期诊断产品中的应用及试剂盒
CN112359040B (zh) * 2020-11-02 2021-09-14 广东省科学院动物研究所 调节let-7基因表达量的制剂在制备调节蜜蜂糖反应性行为制剂中的应用
CN112402440A (zh) * 2020-11-18 2021-02-26 西安组织工程与再生医学研究所 miR-325核酸类似物在制备治疗血窦内皮细胞病理性功能异常相关产品中的应用
CN112458165A (zh) * 2020-12-27 2021-03-09 中山大学孙逸仙纪念医院 一种阿尔茨海默病的预测标志物、检测试剂盒及应用
CN114438187B (zh) * 2021-01-29 2022-08-26 浙江大学医学院附属妇产科医院 一种诊断早期流产的miRNA标志物及其应用
CN114214328A (zh) * 2021-12-17 2022-03-22 川北医学院附属医院 一种核酸药物及其应用
WO2024047115A1 (en) 2022-09-02 2024-03-07 Leibniz-Institut Für Immuntherapie (Lit) THERAPEUTIC USE OF THE miR155 SNP rs377265631
WO2025054607A1 (en) * 2023-09-07 2025-03-13 The Regents Of The University Of California Compositions and methods for treating sarcopenia
CN117257822B (zh) * 2023-09-23 2025-10-28 广州四叶草健康科技有限公司 一种治疗阿尔兹海默病的外泌体混合液及其制备方法
CN117683883B (zh) * 2024-01-11 2024-12-20 山东中医药大学 miR-126-5p在不明原因复发性自然流产诊治中的应用
CN118105400B (zh) * 2024-03-14 2024-08-20 南京市妇幼保健院 一种人子宫内膜间充质干细胞外泌体来源的微小RNA miR-30b及其应用
CN119040464B (zh) * 2024-10-16 2025-04-18 合肥工业大学 一种口腔鳞状细胞癌诊断生物标志物hsa-miR-331-3p及其应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US622690A (en) 1899-04-11 howell
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4522803A (en) 1983-02-04 1985-06-11 The Liposome Company, Inc. Stable plurilamellar vesicles, their preparation and use
US5707331A (en) 1995-05-05 1998-01-13 John R. Wells Automatic multiple-decanting centrifuge
CA2301174C (en) 1997-08-16 2007-11-27 Orthogen Gentechnologie Gmbh A method for inducing therapeutically-effective proteins
DE19903876B4 (de) * 1999-02-01 2006-09-28 Orthogen Gentechnologie Gmbh Verfahren zur in-vitro-Bildung und Anreicherung von Interleukin-1 Rezeptor-Antagonisten
WO2000061256A1 (en) 1999-04-12 2000-10-19 Harvest Technologies Corporation Method and apparatus for producing platelet rich plasma and/or platelet concentrate
JP2002174633A (ja) * 2000-12-08 2002-06-21 Erc:Kk 血清の保存方法
DE10213780A1 (de) * 2002-03-22 2003-11-27 Orthogen Ag Verfahren und Mittel zur Herstellung therapeutisch interessanter Blutzusammensetzungen
HK1079748B (zh) 2002-09-19 2009-02-06 丰收技术股份有限公司 用於无菌可置换单元的容器
AU2004242150B2 (en) 2003-05-19 2008-01-10 Harvest Technologies Corporation Method and apparatus for separating fluid components
KR20070058441A (ko) 2004-07-01 2007-06-08 유니버시티 오브 피츠버그 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 면역억제성 엑소솜
US7893034B2 (en) * 2004-09-02 2011-02-22 Yale University Regulation of oncogenes by microRNAs
DE102006005016A1 (de) † 2006-02-03 2007-08-16 Orthogen Ag Konditionierte Blutzusammensetzung und Verfahren zu deren Herstellung
WO2008088858A2 (en) 2007-01-17 2008-07-24 The Johns Hopkins University Compositions and methods featuring micronas for treating neoplasia
JP2008182921A (ja) 2007-01-29 2008-08-14 Osaka Univ 磁性粒子を用いた遺伝子導入方法
WO2008095096A2 (en) 2007-01-31 2008-08-07 Immune Disease Institute Let-7 microrna and mimetics thereof as therapeutics for cancer
WO2008097230A1 (en) 2007-02-09 2008-08-14 Harvest Technologies Corporation Tissue graft composition comprising autologous bone marrow and purified autologous thrombin
US8288358B2 (en) * 2007-03-26 2012-10-16 Newcastle Innovation Ltd. Therapeutic targets and molecules
US20090124566A1 (en) 2007-06-07 2009-05-14 Duke University Methods and compositions for the treatment of erythrocyte diseases
JP5399011B2 (ja) * 2007-06-28 2014-01-29 三菱化学メディエンス株式会社 組織傷害あるいは細胞増殖性疾患の検出方法
US8716255B2 (en) 2007-08-10 2014-05-06 British Columbia Cancer Agency Branch Microrna compositions and methods for the treatment of myelogenous leukemia
WO2009033140A1 (en) * 2007-09-06 2009-03-12 The Ohio State University Research Foundation Microrna signatures in human ovarian cancer
US20090136942A1 (en) * 2007-09-18 2009-05-28 Oncomedx, Inc. Analysis of Extracellular RNA
US20100323357A1 (en) * 2007-11-30 2010-12-23 The Ohio State University Research Foundation MicroRNA Expression Profiling and Targeting in Peripheral Blood in Lung Cancer
WO2009104051A2 (en) 2007-12-31 2009-08-27 Lu Patrick Y Combinational therapeutics for treatment of prostate cancer using epoxy encapsulated magnetic particles and rnai medicine
US20110003008A1 (en) * 2008-02-22 2011-01-06 Agency For Science, Technology And Research (A*Star) Mesenchymal stem cell particles
US20110160290A1 (en) * 2008-05-21 2011-06-30 Muneesh Tewari Use of extracellular rna to measure disease
AU2010237191A1 (en) 2009-04-07 2011-11-03 Velin-Pharma A/S Method and device for treatment of conditions associated with inflammation or undesirable activation of the immune system
EP2475372B2 (en) 2009-09-10 2020-10-21 Velin-Pharma A/S Method for the preparation of micro-rna and its therapeutic application

Also Published As

Publication number Publication date
CA2773619A1 (en) 2011-03-17
JP2013504542A (ja) 2013-02-07
AU2010294197C1 (en) 2018-08-02
DK2475372T3 (en) 2017-10-23
CN102573856A (zh) 2012-07-11
AU2010294197C9 (en) 2018-09-13
JP5902088B2 (ja) 2016-04-13
CN102573856B (zh) 2016-10-26
CA2773619C (en) 2019-11-12
AU2010294197B2 (en) 2015-08-20
AU2010294197A1 (en) 2012-03-22
WO2011029903A1 (en) 2011-03-17
EP2475372A1 (en) 2012-07-18
US20120172416A1 (en) 2012-07-05
EP2475372B2 (en) 2020-10-21
US9078914B2 (en) 2015-07-14
EP2475372B1 (en) 2017-07-05

Similar Documents

Publication Publication Date Title
DK2475372T4 (da) Fremgangsmåde til fremstilling af micro-RNA og dets terapeutiske anvendelse
DK3795573T3 (da) Bestemte triazolopyraziner, sammensætninger deraf og fremgangsmåder til anvendelse deraf
DK3150240T3 (da) Systemer og fremgangsmåder til fremføring af terapeutiske midler
DK2480574T3 (da) Anti-cd33-antistoffer og deres anvendelse til immunotargeting i behandlingen af cd33-associerede sygdomme
DK3428148T3 (da) Aryloazol-2-yl-cyanoethylaminoforbindelser, fremgangsmåde til fremstilling og fremgangsmåde til anvendelse deraf
DK2419670T3 (da) Leveringsmetode og sammensætninger
DK2602089T3 (da) Resinform til nanotryk og fremgangsmåde til fremstilling deraf
DK3091034T3 (da) Anti-CD40-antistoffer og anvendelser deraf
DK3460056T3 (da) Terapeutiske nukleasesammensætninger og fremgangsmåder
DK3333188T3 (da) Anti-NGF-antistoffer og deres anvendelse
DK3252057T3 (da) Multicykliske forbindelser og fremgangsmåder til anvendelse deraf
DK2632954T4 (da) Midler og fremgangsmåder til behandling af dlbcl
DK3622883T3 (da) Indførerer til medicinsk indretning og fremgangsmåder til at indføre og anvende medicinske indretninger
DK2445912T3 (da) Ny forbindelse anvendelig til behandlingen af degenerative og inflammatoriske sygdomme
DK3121280T3 (da) Antisense-sammensætninger og fremgangsmåder til fremstilling og anvendelse deraf
DK3192520T3 (da) Terapeutiske midler til reducering af niveauerne af parathyreoideahormon
DK2178796T3 (da) Kontinuerlig fremgangsmåde til behandling af væsker og fremstilling af visse bestanddele
DK3382015T3 (da) Fremgangsmåder og produkter til fremstilling af voksestere
DK2408807T3 (da) Fremgangsmåde til terapeutisk anvendelse
DK3263100T3 (da) L-ornithinphenylacetat og fremgangsmåder til fremstilling deraf
NO20085219L (no) Koplingsarrangement og fremgangsmate for forspent sammenkopling
DK2307445T3 (da) Fremgangsmåde til fremstilling af caspofungin og mellemforbindelser heraf
DK2701693T3 (da) Tapentadol til hindring og behandling af depression og angst
DK2627656T3 (da) Fremgangsmåde til fremstilling af dihydropteridinon og intermediater deraf
DK2432798T3 (da) 17-hydroxy-17-pentaflourethyl-estra-4,9(10)-dien-11-aryl-derivat, fremgangsmåde til fremstilling heraf og anvendelse heraf til behandling af sygdomme